LakeShore Biopharma
LSB was delisted on the 19th of September, 2025.
7 hedge funds and large institutions have $330K invested in LakeShore Biopharma in 2025 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
5.89% less ownership
Funds ownership: 7.59% → 1.7% (-5.9%)
22% less funds holding
Funds holding: 9 → 7 (-2)
67% less capital invested
Capital invested by funds: $1.01M → $330K (-$685K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$6.87K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$5.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$108K |
| 2 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$43K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$686 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Fidelity Investments
Boston,
Massachusetts
| $119K | – | – | – |
|
|
HA
2
HHLR Advisors
Grand Cayman,
Cayman Islands
| $76.7K | – | – | – |
|
|
O
3
OrbiMed
New York
| $55.9K | -$108K | -85,629 | -61% |
|
|
SCM
4
Superstring Capital Management
New York
| $31.4K | – | – | – |
|
5
Barclays
London,
United Kingdom
| $25.3K | – | – | – |
|
|
6
Citadel Advisors
Miami,
Florida
| $15.3K | +$5.5K | +4,377 | +41% |
|
|
7
UBS Group
Zurich,
Switzerland
| $6.6K | +$6.87K | +5,469 | +547% |
|
|
8
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | -$43K | -1,048,320 | Closed |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| – | -$686 | -280 | Closed |
|
LSB Hedge Fund Activity: Q2 2025 in Review
7 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in LakeShore Biopharma (LSB) for Q2 2025, worth a combined $330K — down 67% from $1.01M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of LSB and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was UBS Group, adding an estimated $6.87K. The largest seller was OrbiMed, cutting an estimated $108K.
- 7 institutional investors held LakeShore Biopharma (LSB) as of Q2 2025, down from 9 in Q1 2025.
- Funds reported $330K of LakeShore Biopharma stock for Q2 2025, down 67% quarter-over-quarter.
- 0 funds opened new LakeShore Biopharma positions in Q2 2025 and 2 closed out, a net change of -2 holders.
- The largest LakeShore Biopharma buyer in Q2 2025 was UBS Group, an estimated $6.87K added.
- The largest LakeShore Biopharma seller in Q2 2025 was OrbiMed, an estimated $108K sold.
Based on aggregated 13F filings for Q2 2025.